Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BCMA Targeted CAR-NK Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT06045091Phase 1Recruiting
- Sponsor
- Shanghai HRAIN Biotechnology
- Start
- Jul 2023
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in multiple myeloma (MM) and plasma cell leukemia (PCL), sponsored by Shanghai HRAIN Biotechnology. Primary endpoint: Dose Limited Toxicity at 28 days. Started Jul 2023; status: recruiting.
02
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT06045091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045091.